Compare · OBLN vs WST
OBLN vs WST
Side-by-side comparison of Obalon Therapeutics, Inc. (OBLN) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBLN and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $22.59B.
- WST has hit the wire 5 times in the past 4 weeks while OBLN has been quiet.
- WST has more recent analyst coverage (17 ratings vs 0 for OBLN).
- Company
- Obalon Therapeutics, Inc.
- West Pharmaceutical Services Inc.
- Price
- $2.77-14.24%
- $332.00+3.74%
- Market cap
- -
- $22.59B
- 1M return
- -
- +1.85%
- 1Y return
- -
- +48.32%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 17
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest OBLN
- Obalon Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by Obalon Therapeutics, Inc. (Amendment)
- SEC Form SC 13D/A filed by Obalon Therapeutics, Inc. (Amendment)
- SEC Form 4 filed by ARMISTICE CAPITAL, LLC
- SEC Form SC 13D filed by Obalon Therapeutics, Inc.
- SEC Form 3: STANKOVICH THOMAS claimed ownership of 2,613 units of Common Stock
- SEC Form 3 filed by McDougal Lori Courtney
- SEC Form 3 filed by GLADNEY DAN W
- SEC Form 3 filed by MINOCHERHOMJEE ARDA PHD
- SEC Form 3 filed by Bandy Barton P.
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)